title: Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection.
abstract: In 7 of 18 solid-organ transplant recipients with primary human cytomegalovirus (HCMV) infection, HCMV antigenemia levels were unexpectedly found to rise significantly (P = 0.018) during a mean time of 7.3 +/- 3.2 days after initiation of specific antiviral treatment, whereas corresponding levels of viremia dropped significantly (P = 0.043). Thus, shifting to an alternative antiviral drug based solely on increasing antigenemia levels is not justified in this group of patients.
authors.affiliation: Viral Diagnostic Service, IRCCS Policlinico San Matteo, Pavia, Italy. virology@ipv36.unipv.it
authors.forename: G
authors.initials: G
authors.lastname: Gerna
authors.forename: M
authors.initials: M
authors.lastname: Zavattoni
authors.forename: E
authors.initials: E
authors.lastname: Percivalle
authors.forename: P
authors.initials: P
authors.lastname: Grossi
authors.forename: M
authors.initials: M
authors.lastname: Torsellini
authors.forename: M G
authors.initials: MG
authors.lastname: Revello
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects*
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents